MedTrace Logo

Ezetimibe and Orlistat Affect the Intestinal Flora of Hyperlipidemia.

NCT03884127 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2019-03-21

No results posted yet for this study

Summary

At present,the prevalence of hyperlipidemia in Chinese adults is 40.40%,which is related to atherosclerotic cardiovascular disease and diabetes independent risk factors,while increasing the risk of cancer.Lipid metabolism affects the nutritional status of the intestinal epithelium,making the intestine Changes in the microenvironment of the intestinal flora affect the distribution of intestinal flora and eventually lead to bile acid metabolism change.Bile acid is a signal molecule that regulates glucose and lipid and energy metabolism in vivo State.The regulation of intestinal flora may be a new way to treat the imbalance of lipid metabolism,but it is currently sensitive to lipid metabolism the microbiome studies are unclear.In this study, newly diagnosed overweight patients with hyperlipidemia were treated with cholesterol absorption inhibition The drug intervention of ezeomab tablet and orlistat capsule for 12 weeks was observed to observe the changes of intestinal flora and bile acid metabolism after excessive cholesterol and triglyceride production.Clinical screening for the treatment of hyperlipidemia the study provides a reference for bacteria species and prevention and treatment,and provides a research basis for further development of drugs or foods that interfere with lipid metabolism by interfering with intestinal flora.

Conditions

Interventions

DRUG

Ezetimibe 10mg

On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks

DRUG

Orlistat 120 MG

On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks

Sponsors & Collaborators

  • West China Hospital

    collaborator OTHER

  • Fifth Affiliated Hospital of Xinjiang Medical University

    lead OTHER

Principal Investigators

  • haoming tian, master · West China Hospital

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-08-30
Completion
2019-09-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03884127 on ClinicalTrials.gov